Basil Michelle L 4

4 · HAEMONETICS CORP · Filed May 19, 2026

AI-generated summary of this filing

Updated May 19, 2026

Haemonetics (HAE) EVP Michelle L. Basil Receives RSUs; Shares Withheld

What Happened

Michelle L. Basil, EVP and General Counsel of Haemonetics (HAE), was granted 28,424 restricted stock units (RSUs) on May 15, 2026 and, in connection with RSU vesting tax obligations, had 2,913 shares withheld (disposed) at $56.29 per share for $163,973.
The withheld shares reflect tax withholding (transaction code F), not an open-market sale. The RSU award (transaction code A) has no immediate cash value until the units vest.

Key Details

Transaction date: May 15, 2026; Form 4 filed May 19, 2026 (filed within the standard 2-business-day window).
Withheld/disposed: 2,913 shares at $56.29 each, total $163,973 (tax withholding).
Award/acquired: 28,424 RSUs (no per-share price reported for RSUs).
Vesting and plan details: RSUs issued under the Haemonetics Amended and Restated 2019 Long-Term Incentive Compensation Plan; vest 40% on year 1, 40% on year 2, 20% on year 3. Each RSU converts to one share upon vesting.
Shares owned after transaction: not specified in the provided filing.
Footnotes: withholding represents shares used to satisfy tax obligations; award includes unvested RSUs previously reported.

Context

RSU grants are compensation and vest over time; they do not indicate an immediate purchase or sale by the insider until vested and/or sold.
The withheld shares were a routine tax-related disposition (code F), not a directional bet on the stock.

Form 4

Period: 2026-05-15

EVP and General Counsel

Transactions

Tax Payment
Common Stock
[F1][F2]
2026-05-15$56.29/sh−2,913$163,973→ 40,405 total
Award
Common Stock
[F3][F4][F2]
2026-05-15+28,424→ 68,829 total

Footnotes (4)

[F1]Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
[F2]This number includes unvested RSUs previously reported.
[F3]The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
[F4]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Signature

/s/ Thomas V. Powers, attorney-in-fact for Ms. Basil|2026-05-19

1 file